Transcatheter closure of atrial septal communication : impact on P-wave dispersion, duration and arrhythmia in mid-term follow-up by Lelakowska-Pieła, Maria et al.
ORIGINAL ARTICLE
Address for correspondence:  
Paweł T. Matusik, MD, PhD, Department of Electrocardiology, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, ul. Prądnicka 80, 
31–202 Kraków, Poland, tel: +48 12 614 2381, fax: +48 12 614 2226, e-mail: pawel.matusik@wp.eu
Received: 1.03.2018 Accepted: 10.07.2018 Available as AoP: 11.07.2018
Kardiologia Polska Copyright © Polish Cardiac Society 2018
Transcatheter closure of atrial septal 
communication: impact on P-wave dispersion, 
duration, and arrhythmia in mid-term follow-up
Maria Lelakowska1, Monika Komar2, Paweł T. Matusik3, Jadwiga Nessler4, Piotr Podolec2, Maria Olszowska2
1Department of Coronary Disease and Heart Failure, John Paul II Hospital, Krakow, Poland
2Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College,  
John Paul II Hospital, Krakow, Poland
3Department of Electrocardiology, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland 
4Department of Coronary Disease and Heart Failure, John Paul II Hospital, Institute of Cardiology, Jagiellonian University Medical College, 
Krakow, Poland
A b s t r a c t 
Background: Atrial septal communications (ASCs) include atrial septal defects (ASDs) and patent foramen ovale (PFO). 
Aim: The purpose of this study was to assess P-wave dispersion (PWD) and the prevalence of arrhythmia in patients before 
and after ASC closure. 
Methods: We analysed the clinical history and performed 12-lead electrocardiograms, echocardiograms, and 24-h Holter 
electrocardiograms in patients with ASC, before and six months after ASC closure.
Results: We included patients with ASD (n = 56) and PFO (n = 73). PWD before percutaneous ASC closure was predicted by 
right ventricular outflow tract (RVOT) proximal diameter, left atrial area, ASD, smoking, and paroxysmal dyspnoea, R2 = 0.67; 
p < 0.001. RVOT proximal diameter was an independent predictor of PWD, both in patients with ASD and PFO. Six months 
after successful closure of ASC, a reduction in PWD was observed in the whole group of patients as well as in patients with 
ASD and PFO considered separately. A decrease in PWD was associated with reduction of maximum P-wave duration. At 
the same time, in the whole group, we noticed a reduction in the number of supraventricular and ventricular extrasystolic 
beats and fewer atrial fibrillation (AF) episodes, p < 0.04 for all variables. Postprocedural AF episodes in patients with ASD 
were predicted by PWD of 80 ms.
Conclusions: Percutaneous closure of ASC is associated with a reduction of PWD and fewer arrhythmia episodes six months 
after the procedure. PWD predicts AF episodes after ASD closure. 
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INTRODUCTION
Atrial septal defects (ASDs) are the most common congenital 
heart defects in adults, and they comprise about 40% of con-
genital heart defects diagnosed in patients over 40 years old. 
Classification of ASDs is based on its anatomical location and 
the presence of concomitant anomalies. The risk for devel-
opment of pulmonary vascular disease with right ventricular 
insufficiency indicates the necessity for the referral of these 
patients for closure of the defect. Percutaneous closure with 
an occluder can only be performed in ostium secundum 
ASD (ASD II), which is possible in 96% to 100% of cases. On 
the other hand, patent foramen ovale (PFO), a remnant of 
interatrial communication present in foetal life, is diagnosed in 
25% to 30% of post-mortem examinations. PFO is a potential 
space between the septum primum and septum secundum, 
which may cause right-to-left shunt after changes in pressure 
gradient between the atria. According to previous observa-
tions, the presence of PFO may be associated the occurrence 
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of a cryptogenic stroke. Current recommendations advise 
consideration of PFO closure in case of recurrent cryptogenic 
stroke despite optimal pharmacotherapy. 
Implantation of the occluder is performed under fluoros-
copy and transoesophageal or intracardiac echocardiography 
guidance [1–4]. 
The electrophysiological mechanisms of atrial arrhythmias 
in patients with atrial septal communication (ASC), includ-
ing ASD and PFO, may involve increased P-wave disper-
sion (PWD). P-wave duration and its dispersion reflect the 
heterogenous propagation of sinus beats and disturbances of 
intra- and interatrial conduction [5–11]. 
The main aims of the study were to determine the fac-
tors influencing PWD in patients with ASC and to assess its 
changes after ASC closure. Additionally, we aimed to evalu-
ate the prevalence of arrhythmia in patients before and after 
ASC closure. 
METHODS
Patients
In this prospective study we included patients scheduled for 
percutaneous closure of ASC (study group).
Patients were included in the study group if they met the 
following criteria: (1) they were scheduled for percutaneous 
closure of a single ASD or PFO; (2) their P-waves were easily 
visible in 12-lead resting electrocardiogram (ECG) and the 
images obtained by transthoracic echocardiography (TTE) 
were of good quality.
Exclusion criteria comprised (1) chronic atrial fibrillation 
(AF); (2) previous cardiac surgery, AF ablation, or cardiovascu-
lar implantable electronic device placement; (3) left ventricu-
lar ejection fraction (LVEF) below 50% or dementia; (4) the 
presence of significant leaking around the implanted occluder; 
(5) the presence of significant valvular heart disease and/or 
other congenital cardiovascular defect; (6) cardiomyopathy; 
and (7) non-echogenicity (difficult-to-interpret echocardi-
ography imaging) and/or poor visibility of P-waves in ECG.
Clinical assessment
All patients provided their clinical history and underwent 
clinical examination. Structural cardiovascular abnormalities, 
and comorbidities were diagnosed on the basis of commonly 
accepted standards. ASD and PFO were diagnosed after clini-
cal assessment, TTE, and transoesophageal echocardiography 
(TEE), which were also used to identify patients eligible for 
percutaneous ASC closure. Diagnosis and eligibility for the 
procedure were confirmed during cardiac catheterisation 
immediately before implantation of the occluder.
12-lead resting ECG 
Electrocardiogram was recorded at a speed of 50 mm/s, with 
augmentation of 1 cm = 1 mV. P-wave duration was assessed 
in five consecutive sinus beats. In each ECG lead the P-wave 
was manually assessed with a standard ECG ruler, with accu-
racy up to 10 ms. P-wave duration was defined as the distance 
from the beginning (positive or negative deflection from the 
isoelectric line) to its end (return to the isoelectric line), us-
ing 4× magnification of the image. Maximum and minimum 
P-wave durations were determined. PWD was defined as 
the difference between the maximum and minimum P-wave 
duration in a 12-lead resting ECG. The mean PWD value 
was calculated from five consecutive measurements and was 
rounded to full values. The abovementioned parameters were 
measured by an experienced investigator who was blinded to 
the patients’ characteristics. At the time of measurements, the 
patients were not taking any medications affecting intra- and 
interatrial conduction [10, 11].
24-h Holter ECG monitoring, TTE, and TEE
Recording of the 24-h Holter ECG monitoring was performed 
using a three-channel DelMar Avionics model 563 (Reynolds, 
Irvine, CA, USA) device. Analyses of the recordings were done 
with DelMar Avionics (Reynolds, Irvine, CA, USA) software, 
and the following were determined: mean, minimum and 
maximum heart rate (HR) and the presence of supraven-
tricular extrasystolic beats (SVEB), ventricular extrasystolic 
beats (VEB), and AF episodes [12–14]. AF was defined as an 
episode of AF lasting at least 30 s during 24-h Holter ECG 
monitoring. Echocardiography was performed according to 
guideline recommendations [15–17] using a Toshiba Power 
Vision model 7000 (Toshiba, Otawara, Japan) ultrasound 
system and ultrasound probes with a frequency of 2.5 to 
3.5 MHz. It included M-mode imaging, two-dimensional (2D) 
imaging, pulse wave Doppler, continuous wave Doppler, and 
colour flow Doppler imaging. Assessment of ASC size and 
location was performed in 2D mode on the basis of standard 
views. During TEE, morphology of atrial septum was assessed 
in bicaval view and high longitudinal view. Enlarged left atrium 
(LA) was defined as LA area over 20 cm2, while enlarged right 
atrium (RA) was defined as RA area over 17 cm2.
All measurements were performed before percutaneous 
closure of ASD or PFO and six months after the procedure. 
The study was in accordance with ethical standards, and all 
patients gave written consent to undergo the studies and 
procedure according to Polish/European Society of Cardiol-
ogy standards.
Statistical analysis
Quantitative variables were presented as the mean ± stan-
dard deviation, median, range, and/or interquartile range 
(IQR). Qualitative variables were presented as number and/or 
frequency. The Shapiro-Wilk test was used to verify the nor-
mality of distribution for quantitative variables. Student t test 
or Mann-Whitney U test was used to assess the associations 
of qualitative variables between patients with ASD and PFO. 
Verification of the relationship between two qualitative 
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variables was performed with the c2 test or Fisher exact test. 
Analysis of changes in quantitative variables, before and after 
the procedure, was performed using Wilcoxon matched-pairs 
test, and in the qualitative (dichotomous) variables with 
McNemar’s test for repeated measures. The strength of the 
relationship between two quantitative variables was assessed 
using the Spearman correlation coefficient (rs). A p-value 
of < 0.05 was assumed as significant.
Selected variables associated with PWD (p < 0.05) in 
univariate analysis, which did not substantially correlate 
(including correlation coefficient ≥ 0.6) with other independ-
ent variables, were included into multiple linear regression 
analyses. The selection of variables that significantly influenced 
the dependent variable was performed using the stepwise 
backward regression. R2 was calculated, and assessment of 
model adequacy was measured using Fk,n-k-1 test, where k is 
a number of variables in a model, and n is a number of pa-
tients in a group. 
To determine the cut-off point of PWD for the presence 
of AF or SVEB after the procedure, receiver operating char-
acteristic (ROC) curves were drawn. Positive thresholds were 
determined using the Youden index. Statistical analyses were 
performed with STATISTICA 12 (StatSoft, Tulsa, OK, USA) or 
IBM SPSS Statistics (version 24, IBM Corp., Armonk, NY, USA, 
for multiple regression analysis).
RESULTS
Patient characteristics
We included 129 patients (59 men) aged from 19 to 76 years 
(mean age 44.5 ± 13.4 years) referred for percutaneous 
closure of ASD (n = 56) or PFO (n = 73). Patients with ASD 
were older (p < 0.001) and more often female (p < 0.001) 
than patients with PFO.
The clinical characteristics of the studied patients are 
shown in Table 1. 
ASD, PFO, and procedural characteristics
The mean resting size of ASD was 11.6 ± 5.9 mm (range 
3.4–24 mm), while the size after dilatation with a diagnostic 
catheter was 20.3 ± 6.6 mm (range 7.1–30.9 mm). Mean 
size of PFO was 9.1 ± 3.1 mm (range 3–15.4 mm), while 
separation of the septum primum and secundum after contrast 
administration was 3.6 ± 1.6 mm (range 2–8.9 mm). Closure 
of ASC was performed with occluders with a mean size of 
25 ± 4.9 mm (range 7–34 mm). Mean fluoroscopy time was 
7 ± 4.8 min (range 2.4 to 17 min), while mean radiation 
absorbed dose was 76.4 ± 135 mGy (range 5 to 580 mGy).
Associations with PWD and related variables
P-wave dispersion correlated with several clinical, echo-
cardiographic (including left and right atrial areas as well 
as right ventricular dimensions), and interestingly also with 
procedure-related parameters (Table 2). PWD in ASC was 
predicted by right ventricular outflow tract (RVOT) proximal 
diameter (unstandardised coefficient B: 0.78; 95% confidence 
interval [CI] 0.47–1.08), LA area (B: 1.03; 95% CI 0.56–1.50), 
ASD (B: 8.67; 95% CI 3.21–14.13), smoking (B: 11.93; 95% 
CI 5.69–18.17), and paroxysmal dyspnoea (B: 6.84; 95% 
CI 0.06–13.62), R2 = 0.67; p < 0.001 (Table 3). Detailed 
analysis of PWD predictors in patients with ASD and PFO is 
shown in Table 3.
The procedure was associated with significant re-
duction in PWD in patients with ASD (61.6 ± 17.1 ms 
vs. 35.8 ± 22.0 ms; p < 0.001) and PFO (36.7 ± 18.6 ms 
vs. 18.1 ± 9.7 ms; p < 0.001; Table 4). It was related to 
reduction of maximum P-wave duration also in patients with 
ASD (134 ± 11.4 ms vs. 107 ± 18.6 ms; p < 0.001) and 
PFO (111 ± 15.5 ms vs. 91.7 ± 14.6 ms; p < 0.001). On the 
other hand, minimum P-wave duration did not differ before 
the procedure and at six-month follow-up (Table 4).
Results of Holter monitoring  
and prevalence of arrhythmia
After the procedure maximum, minimum, and mean 
Holter-derived HR decreased in the whole study group and 
in the group of ASD patients, while in patients with PFO 
a decrease was observed only in maximum HR (Table 4).
In the whole study group the numbers of SVEBs and 
VEBs before the procedure were 54.0 (4.0–242.0)/day and 
1.0 (0.0–6.0)/day, respectively.
The number of SVEBs (p < 0.001 for patients with 
ASD and PFO analysed together and separately) and VEBs 
(p = 0.038 for all patients who underwent a successful pro-
cedure) was lower after percutaneous closure of ASC. On the 
other hand, in patients with ASD or PFO considered separately 
the number of VEBs did not change (p = 0.145 and p = 0.156, 
respectively). The percentages of patients with extrasystolic 
beats reduced by a factor of approximately two (SVEB: 83% 
vs. 43%, p < 0.001; VEB: 63% vs. 38%, p < 0.001). After 
the procedure patients with ASD and PFO did not differ with 
regards to SVEB number (median [IQR]: 4 [0–349] vs. 0 [0–10] 
SVEB/day, p = 0.182). In patients in whom arrhythmias per-
sisted, their intensity according to VEB (p = 0.466) and SVEB 
(p = 0.37) did not change. AF episodes were observed in 
25 (19.4%) patients (18 patients with ASD and seven patients 
with PFO) before the procedure and in seven (5.4%) patients 
(all with ASD) after ASC closure (p < 0.001) during 24-h 
Holter ECG monitoring. In patients with AF, PWD before and 
after the procedure was 70.4 ± 11.5 ms and 48.7 ± 23.0 ms 
(p < 0.001), respectively, while in patients without AF it 
was 42.1 ± 20.4 ms and 20.8 ± 12.6 ms (p < 0.001). In 
patients with AF, maximum P-wave duration before and after 
the procedure was 135.7 ± 9.5 ms and 115.7 ± 21.1 ms 
(p < 0.001), respectively, while in patients without AF it 
was 117.5 ± 17.7 ms and 94.7 ± 15.0 ms (p < 0.001). 
ROC curve has shown 80 ms as a cut-off point of PWD 
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Table 1. Clinical characteristics of patients undergoing closure of atrial septal communication
Variable ASD (n = 56) PFO (n = 73) p
Age [years] 49.8 ± 13.3 40.5 ± 12.0 < 0.001
Male sex 12 (21.3) 47 (64.4) < 0.001
Comorbidities and CVD risk factors:
Arterial hypertension 17 (30.4) 3 (4.1) < 0.001
Pulmonary hypertension 19 (33.9) 0 (0.0) < 0.001
Hyperlipidaemia 15 (26.8) 7 (9.6) 0.004
Diabetes mellitus 4 (7.1) 1 (1.4) 0.001
Obesity 3 (5.4) 2 (2.7) 0.401
Smoking 14 (25.0) 9 (12.3) 0.033
Anaemia 0 (0.0) 1 (1.4) 0.999
Migraine 0 (0.0) 11 (15.1) 0.003
Vasovagal syndrome 1 (1.8) 3 (4.1) 0.643
Stroke/TIA 4 (7.1) 24 (32.9) < 0.001
Atrial fibrillation 17 (30.4) 8 (11.0) < 0.001
Electrocardiographic parameters:
Maximum HR [bpm] 123.7 ± 11.0 123.5 ± 13.4 0.718
Minimum HR [bpm] 52.0 ± 6.4 47.7 ± 6.0 < 0.001
Mean HR [bpm] 73.3 ± 6.3 69.4 ± 5.7 0.001
SVEBs [beats per day] 748.6 ± 2127 147.2 ± 505.1 < 0.001
VEBs [beats per day] 252.3 ± 1734 70.2 ± 331 0.017
Maximum P-wave duration [ms] 133.9 ± 11.5 110.8 ± 15.6 < 0.001
Minimum P-wave duration [ms] 73.0 ± 9.9 73.4 ± 12.7 0.631
P-wave dispersion [ms] 60.9 ± 18 37.3 ± 18.7 < 0.001
Echocardiographic parameters:
Left-to-right shunt 54 (96.4) 41 (56.2) < 0.001
Interatrial septal aneurysm 11 (19.6) 50 (68.5) < 0.001
Enlarged LA 35 (62.5) 14 (19.1) < 0.001
Enlarged RA 37 (66.1) 14 (19.2) < 0.001
Enlarged right ventricle 33 (58.9) 16 (20.6) < 0.001
Myocardial hypertrophy 9 (16.1) 4 (5.5) 0.007
Device:
Cardia Ultrasept ASD occluder 4 (7.1) 0 (0.0) –
Cardia Ultrasept PFO occluder 0 (0.0) 69 (94.5) –
Memopart ASD occluder 51 (91.1) 0 (0.0) –
No implanted device 1 (1.8) 4 (5.5) –
Procedure:
Without complications 55 (98.2) 69 (94.5)
Stopped due to complications 0 (0.0) 1 (1.4) NS
Unsuccessful 1 (1.8) 3 (4.1)
Medications:
CCB 18 (32.1) 1 (1.4) < 0.001
b-blocker 17 (30.4) 10 (13.7) 0.015
ACEI 17 (30.4) 5 (6.8) < 0.001
Data are presented as mean ± standard deviation or number (percentage). ACEI — angiotensin converting enzyme inhibitor; ASD — atrial septal 
defect; CCB — calcium channel blocker; CVD — cardiovascular disease; HR — heart rate; LA — left atrium; NS — non-significant; PFO — patent 
foramen ovale; RA — right atrium; SVEB — supraventricular extrasystolic beat; TIA — transient ischaemic attack; VEB — ventricular extrasystolic beat
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Table 2. Spearman correlations (rs) between quantitative variables and maximum P-wave duration and P-wave dispersion before 
closure of atrial septal communication
Variables (n = 124) Maximum P-wave duration rs (p-value) P-wave dispersion rs (p-value)
ASC ASD PFO ASC ASD PFO
Age [years] 0.22 (0.017) 0.39 (0.003) –0.23 (0.047) 0.22 (0.016) 0.46 (< 0.001) –0.14 (0.239)
NYHA class 0.29 (0.001) 0.12 (0.384) 0.21 (0.076) 0.30 (0.001) 0.17 (0.211) 0.23 (0.047)
P-wave dispersion [ms] 0.88 (< 0.001) 0.92 (< 0.001) 0.67 (< 0.001) – – –
Minimum HR [bpm] 0.39 (<0.001) 0.31 (0.019) 0.23 (0.046) 0.33 (< 0.001) 0.21 (0.122) 0.22 (0.065)
Echocardiography:
RVOT prox. [mm] 0.47 (< 0.001) 0.41 (0.002) 0.22 (0.057) 0.59 (< 0.001) 0.48 (< 0.001) 0.42 (< 0.001)
TAPSE [mm] 0.28 (0.002) 0.26 (0.052) 0.21 (0.075) 0.22 (0.016) 0.24 (0.069) 0.09 (0.473)
RVD1 [mm] 0.53 (< 0.001) 0.50 (< 0.001) 0.27 (0.022) 0.52 (< 0.001) 0.50 (< 0.001) 0.19 (0.102)
RVD2 [mm] 0.57 (< 0.001) 0.27 (0.043) 0.50 (< 0.001) 0.58 (< 0.001) 0.33 (0.014) 0.51 (< 0.001)
RVD3 [mm] 0.44 (<0.001) 0.30 (0.027) 0.20 (0.089) 0.43 (<0.001) 0.30 (0.023) 0.19 (0.112)
LA area [cm2] 0.60 (< 0.001) 0.73 (< 0.001) 0.13 (0.273) 0.69 (< 0.001) 0.75 (< 0.001) 0.33 (0.005)
RA area [cm2] 0.63 (< 0.001) 0.67 (< 0.001) 0.23 (0.052) 0.63 (< 0.001) 0.74 (< 0.001) 0.24 (0.042)
LVSD [mm] –0.31 (< 0.001) 0.07 (0.589) 0.08 (0.491) –0.25 (0.005) 0.16 (0.231) –0.03 (0.820)
Qp/Qs ratio 0.70 (< 0.001) 0.38 (0.003) * 0.61 (< 0.001) 0.56 (< 0.001) *
Procedure:
Fluoroscopy time [min] 0.46 (< 0.001) 0.31 (0.022) 0.30 (0.010) 0.42 (< 0.001) 0.35 (0.008) 0.24 (0.039)
RAD [mGy] 0.51 (< 0.001) 0.38 (0.004) 0.39 (0.001) 0.55 (< 0.001) 0.38 (0.004) 0.52 (<0.001)
ASC — atrial septal communication; HR — heart rate; NYHA — New York Heart Association; RAD — radiation absorbed dose; RVOT prox. —  
proximal right ventricular outflow tract; TAPSE — tricuspid annular plane systolic excursion; RVD1 — basal right ventricular linear dimension; 
RVD2 — mid-cavity right ventricular linear dimension; RVD3 — right ventricular longitudinal dimension; LVSD — left ventricular systolic dimension; 
Qp/Qs ratio — pulmonary-to-systemic blood flow ratio; *Qp/Qs ratio = one in all patients
Table 3. Multiple regression analysis of predictors of P-wave dispersion before the procedure in patients with atrial septal  
communication
Standardised  
coefficient 
Beta
Unstandardised  
coefficient B
95% confidence 
interval for B
p
ASC (R2 = 0.67; F5,123 = 49.46; p < 0.001)
RVOT prox. [mm] 0.32 0.78 0.47–1.08 < 0.001
Left atrial area [cm2] 0.32 1.03 0.56–1.50 < 0.001
ASD 0.20 8.67 3.21–14.13 0.002
Smoking 0.21 11.93 5.69–18.17 <0.001
Paroxysmal dyspnoea 0.12 6.84 0.06–13.62 < 0.05
ASD (R2 = 0.59; F2,53 = 38.83; p < 0.001)
RVOT prox. [mm] 0.28 0.52 0.18–0.86 0.003
Left atrial area [cm2] 0.64 1.48 1.06–1.90 < 0.001
PFO (R2 = 0.56; F3,69 = 28.98; p < 0.001)
RVOT prox. [mm] 0.48 1.28 0.83–1.72 < 0.001
Smoking 0.29 16.29 6.97–25.61 < 0.001
Tricuspid insufficiency 0.41 17.29 10.54–24.03 < 0.001
Abbreviations — see Tables 1 and 2
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before the procedure for the presence of an AF episode six 
months after successful closure of ASC (Fig. 1A) (area under 
the curve [AUC] = 0.949; sensitivity = 85.7%; specific-
ity = 93.2%; p < 0.001). The same cut-off point was deter-
mined for patients with ASD considered separately (Fig. 1B) 
(AUC = 0.885; sensitivity = 85.7%; specificity = 83.3%; 
p < 0.001). ROC curve of PWD before the procedure for the 
presence of SVEBs six months after successful closure of ASC 
is shown in Figure 1C (AUC = 0.641; sensitivity = 58.9%; 
specificity = 64.7%; p = 0.005). There were no AF episodes 
observed after PFO closure. ROCs for the prediction of 
SVEB after ASD or PFO closure, considered separately, were 
non-significant (p = 0.068 and p = 0.104; respectively). In 
the whole study group, PWD of at least 80 ms was observed 
in 14 patients (all with ASD). Six (42.9%) of them had an AF 
episode after the procedure. On the other hand, only one 
(2.4%) patient with lower PWD had AF after ASD closure. In 
the whole study group, PWD of at least 60 ms was observed 
in 57 patients; 33 (57.9%) of them had SVEB after the proce-
dure. Lower PWD was noted in 67 patients, and 23 (34.3%) 
of them had at least one SVEB after the procedure.
DISCUSSION
In patients with ASC, abnormalities in intra- and interatrial 
conduction reflected by increased P-wave duration and its 
dispersion (dispersion of depolarisation/repolarisation) are 
observed [18]. PWD in ASD was predicted by RVOT proximal 
diameter and LA area, while in patients with PFO, besides 
RVOT proximal diameter and smoking, tricuspid insufficiency 
was also found to play an important role in PWD prediction.
Ndrepepa et al. [19] found that electrical activity obtained 
from surface ECG recordings correlates with conduction in 
certain parts of the atria, and this is not just the effect of dif-
ferent projections of the P-wave vector, which result from 
difference in angles between it and ECG lead axis. Similarly to 
our observations, Yavuz et al. [20] noted increased maximum 
Table 4. Changes in selected electrocardiographic parameters before and six months after a successful closure of atrial septal 
communication
Before 6-m FU Before 6-m FU Before 6-m FU
ASC Max HR [bpm] Min HR [bpm] Mean HR [bpm]
Mean 123.6 118.9 49.6 45.9 71.1 67.8
SD 12.3 10.8 6.5 5.5 6.2 5.1
p < 0.001 < 0.001 < 0.001
ASC Max P-wave duration [ms] Min P-wave duration [ms] P-wave dispersion [ms]
Mean 120.9 98.5 73.3 72.6 47.5 25.6
SD 18.1 18.2 11.5 9.9 21.8 18.5
p < 0.001 NS < 0.001
ASD Max HR [bpm] Min HR [bpm] Mean HR [bpm]
Mean 123.7 113.6 52.0 44.0 73.3 66.2
SD 11.0 9.3 6.4 4.5 6.3 5.3
p < 0.001 < 0.001 < 0.001
ASD Max P-wave duration [ms] Min P-wave duration [ms] P-wave dispersion [ms]
Mean 133.9 106.9 73.0 71.6 60.9 35.3
SD 11.5 18.5 9.9 8.6 18.0 22.0
p < 0.001 0.218 < 0.001
PFO Max HR [bpm] Min HR [bpm] Mean HR [bpm]
Mean 123.5 123.1 47.7 47.4 69.4 69.1
SD 13.4 10.0 6.0 5.7 5.7 4.5
p 0.04 0.992 0.816
PFO Max P-wave duration [ms] Min P-wave duration [ms] P-wave dispersion [ms]
Mean 110.8 91.9 73.4 73.3 37.3 18.6
SD 15.6 14.9 12.7 10.8 18.7 10.5
p < 0.001 0.676 < 0.001
Data are presented as means and standard deviations. 6-m FU — six-month follow-up; max — maximum; min — minimum; NS — non-significant; 
for other abbreviations see Table 1 and 2
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P-wave duration and PWD in children with ASD, compared 
to controls, and observed maximum P-wave duration and 
PWD reduction within the first year after surgical ASD closure. 
Baspinar et al. [21] noted a decrease in PWD even one week 
after surgical (but not transcatheter) closure of secundum-type 
ASD. Lack of PWD reduction among children who underwent 
transcatheter closure could result at least in part from larger 
sizes of ASD in patients who underwent the surgical closure. 
Interestingly, at the same time, in the transcatheter ASD clo-
sure group of patients, a reduction of HR was observed [21]. 
On the other hand, immediately after ASD closure an in-
crease in both maximum P-wave duration and PWD was 
noted, irrespective of the device used (Amplatzer vs. Figulla 
septal occluder) [22]. Our results underline the dynamics of 
myocardial remodelling after ASD closure.
Increased PWD (> 40 ms) was reported to have a signifi-
cant influence on the risk of AF development, both idiopathic 
and associated with diseases influencing cardiovascular func-
tion [23–25]. Numerous experimental and clinical studies 
have shown that AF/atrial flutter in heart defects (including 
Figure 1. Receiver operating characteristic (ROC) curve for the determination of the cut-off point of P-wave dispersion before 
the procedure, for the presence of an atrial fibrillation episode six months after a successful closure of atrial septal communica-
tion (ASC) (A), and atrial septal defect considered separately (B). ROC curve for the determination of the cut-off point of P-wave 
dispersion before the procedure, for the presence of supraventricular extrasystolic beats six months after successful ASC closure (C);  
AUC — area under the curve. Positive thresholds were determined using the Youden index
A B
C
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heart defects with shunts) is caused by atrial wall remodel-
ling, defined not only as the change in the size and shape, 
but also as the changes of structure and proportions between 
muscular and fibrotic tissue, along with changes in metabolism 
and myocyte electrophysiological properties. The persistence 
of arrhythmias, despite the closure of the defect, may be 
a consequence of permanent atrial remodelling resulting from 
long-term increase in intra-atrial pressure [5, 14]. Interestingly, 
in our group of patients who underwent percutaneous ASD 
closure, AF episodes six months after the procedure could be 
predicted by a PWD of at least 80 ms. 
Similar results with regards to PWD were observed in 
a smaller group of ASD patients and were associated with 
the lack of enlarged RA size normalisation three months after 
the procedure [26]. 
Atrial septal communication closure may be associated 
with complications [27–29]; however, closure of ASC with an 
occluder does not cause significant conduction disorders but 
transiently increases supraventricular heart rhythm disorders 
and leads to a significant increase in mean and maximal HR 
a month after the procedure [5, 14, 18]. It may be associ-
ated with procedure-related injuries, instrumentation during 
catheterisation, invasive measurement of the defect, and at-
tempts of passing the catheter through the ASC. Previously, 
significant correlations were found between fluoroscopy time 
and occluder size, which reflect the procedure difficulty, and 
the number of SVEBs one month after the procedure [5, 14]. 
The more time is needed for proper occluder placement, the 
greater the probability of atrial wall and interatrial septum in-
jury, which may induce supraventricular tachyarrhythmias. In 
our study, six months after the procedure, these abnormali-
ties were absent. However, interestingly, both fluoroscopy 
time and radiation absorbed dose correlated with PWD and 
maximum P-wave duration.
At present, the predominant view is that in some pa-
tients closure of the defect may prevent recurrence of atrial 
arrhythmias and is associated with a reduced prevalence of 
arrhythmias [18]. In our study, the numbers of SVEBs and VEBs 
before the procedure were low (from a clinical point of view). 
However, it should not be expected that the correction of 
the defect would lead to sinus rhythm restoration in patients 
with chronic AF [30]. Our observations are consistent with the 
results obtained by other authors and highlight also the po-
tential impact of smoking and hypoxaemia on PWD [31, 32]. 
Our study has several limitations. The assessment of PWD 
was performed manually. However, this method could be use-
ful in clinical practice because it is easy to perform and seems 
reasonable in light of previous studies [10, 26]. Measurements 
of P-wave duration and dispersion were conducted according 
to generally accepted rules [10, 11, 26]. We did not assess 
inter- or intra-observer variability because our aim was not 
to set normal values for P-wave duration and dispersion, but 
to investigate the role of PWD in the prediction of AF after 
percutaneous closure of ASC. Echocardiography and Holter 
ECG monitoring were performed only twice; more studies 
would provide more detailed dynamics of the observed 
changes. Moreover, prolonged ECG monitoring to detect 
and quantify atrial arrhythmias would be advantageous and 
could result in a higher number of patients with diagnosed AF 
episodes during follow-up. Patients with ASD and PFO differ 
with regards to pathophysiology, symptomatology, natural 
history, and indications for the procedure.
In conclusion, in patients before ASC closure the most 
important factors influencing PWD are increased left atrial 
area, RVOT proximal diameter, presence of ASD, history of 
smoking, and paroxysmal dyspnoea. Percutaneous closure of 
ASC is associated with reduction of PWD and fewer episodes 
of arrhythmia six months after the procedure. PWD predicts 
AF episodes after ASD closure. 
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